



NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW

## PRESS RELEASE

### **CERBA EUROPEAN LAB S.A.S. ANNOUNCES LAUNCH OF OFFERING OF €355,000,000 SENIOR SECURED NOTES DUE 2020**

**Saint-Ouen-L'Aumône, France — Monday 14 January 2013.** Cerba European Lab S.A.S. ("Cerba European Lab") today announced that it has launched an offering of €355,000,000 aggregate principal amount of its senior secured notes due 2020.

The proceeds from the offering, if completed, are expected to be used to (i) repay in full the outstanding amounts under the existing senior and mezzanine facilities, including accrued interest and prepayment penalties thereunder, (ii) pay the termination costs of certain existing swaps, (iii) increase cash on balance sheet to be used for general corporate purposes and (iv) pay related fees and expenses in connection with the offering and related transactions.

#### **About Cerba European Lab**

Cerba European Lab is a leading European clinical pathology laboratory that provides routine and specialized clinical laboratory testing services primarily in France, Belgium and Luxembourg and supports pharmaceutical and biotechnology companies worldwide in the clinical trial phase of their drug development processes.

#### **Cautionary Statement**

This announcement does not constitute an offer of securities for sale in the United States. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States in connection with this transaction.

This announcement does not constitute or form part of an offer or solicitation of an offer to purchase or subscribe for securities in France. The securities referred to herein may not be and will not be offered or sold to the public in France except to qualified investors ("investisseurs qualifiés") acting for their own account, as defined in, and in accordance with Articles L. 411-2, D. 411-1 and D. 411-4 of the French Monetary and Financial Code.

This document and the offer when made are only addressed to and directed at persons in member states of the European Economic Area ("EEA") who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC, as modified by Directive 2010/73/EU) (the "Prospectus Directive") ("Qualified Investors").

In the United Kingdom, this document is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and Qualified Investors falling within Article 49 of the Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This document must not be acted on or relied on (i) in the UK, by persons who are not relevant persons, and (ii) in any member state of the EEA other than the UK, by persons who are not Qualified Investors. Any investment or investment activity to which this document relates is available only to (i) in the UK,

relevant persons, and (ii) in any member state of the EEA other than the UK, Qualified Investors, and will be engaged in only with such persons.

### **Forward-Looking Statements**

This press release may include forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding Cerba European Lab S.A.S.’s or any of its affiliates’ intentions, beliefs or current expectations concerning, among other things, Cerba European Lab S.A.S.’s or any of its respective affiliates’ results of operations, financial condition, liquidity, prospects, growth, strategies and the industries in which they operate. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that Cerba European Lab S.A.S. or any of its respective affiliates’ actual results of operations, financial condition and liquidity, and the development of the industries in which they operate may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if Cerba European Lab S.A.S. or any of its respective affiliates’ results of operations, financial condition and liquidity, and the development of the industries in which they operate are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.

Contact Cerba European Lab :

Pascale LAURENT  
pascale.laurent@cerba-european-lab.com